Prescription Medicine for Hemorrhoids: When Over-the-Counter Fails and What Your Doctor Will Actually Prescribe

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Only 4 prescription medications for hemorrhoids have strong evidence: nitroglycerin ointment, nifedipine gel, topical diltiazem, and prescription-strength hydrocortisone combinations
• Most prescription treatments target internal hemorrhoids with thrombosis or grade III-IV prolapse, not simple external irritation
• The prescription threshold is typically 2 to 3 weeks of failed OTC management plus objective findings on examination
• GLP-1 medications increase hemorrhoid risk through chronic constipation, making prescription intervention more common in weight-loss patients

Direct answer (40-60 words)

Prescription hemorrhoid medications fall into four categories: calcium channel blockers (nifedipine, diltiazem) that relax anal sphincter pressure, nitrates (nitroglycerin ointment) that improve blood flow, prescription-strength corticosteroids for severe inflammation, and topical anesthetics stronger than OTC options. Most are reserved for grade III-IV internal hemorrhoids or thrombosed external hemorrhoids after conservative management fails.

Table of contents

1. The prescription threshold: when OTC stops working
2. The four prescription medication classes that work
3. What most articles get wrong about hemorrhoid prescriptions
4. The clinical grading system that determines treatment
5. Nitroglycerin ointment: the mechanism and the headache problem
6. Calcium channel blockers: nifedipine and diltiazem
7. Prescription corticosteroids: when inflammation is the problem
8. The GLP-1 connection: why weight-loss patients see more hemorrhoids
9. The decision tree: OTC vs prescription vs procedure
10. When steroid creams make things worse
11. The evidence gap in hemorrhoid pharmacotherapy
12. FAQ
13. Sources

The prescription threshold: when OTC stops working

The clinical threshold for prescription hemorrhoid medication is not arbitrary. Most providers follow a conservative escalation:

Week 1-2: OTC management (fiber, sitz baths, hydrocortisone 1%, witch hazel) Week 3-4: If symptoms persist, examination to grade severity Week 4+: Prescription medication if grade II-III internal hemorrhoids or thrombosed external hemorrhoids confirmed

The examination matters because symptoms alone don't predict what treatment will work. A patient reporting "severe pain" might have a small thrombosed external hemorrhoid (responds to excision, not medication) or grade IV prolapsed internal hemorrhoids (responds to banding or surgery, not topical treatments).

The prescription decision is driven by three factors:

1. Anatomical grade. Internal hemorrhoids are graded I through IV based on prolapse. External hemorrhoids are either thrombosed or not.
2. Duration. Acute symptoms under 2 weeks respond to OTC. Chronic symptoms beyond 4 weeks need evaluation.
3. Failure of conservative management. If fiber supplementation (25 to 30 grams daily), adequate hydration, sitz baths, and OTC hydrocortisone haven't improved symptoms after 14 days, prescription options open.

A 2021 systematic review in Diseases of the Colon and Rectum (Sandler et al.) found that 68% of patients with grade I-II hemorrhoids responded to conservative management alone within 4 weeks. The remaining 32% required prescription intervention or office procedures.

The four prescription medication classes that work

The prescription hemorrhoid pharmacopeia is smaller than most patients expect. Only four drug classes have consistent evidence:

Drug class	Mechanism	Typical prescription	Evidence grade	Common side effect
Topical nitrates	Relax internal anal sphincter, improve venous drainage	Nitroglycerin 0.2-0.4% ointment TID	Moderate (RCTs)	Headache (30-50% of users)
Calcium channel blockers	Reduce anal sphincter pressure	Nifedipine 0.2-0.3% gel BID or diltiazem 2% ointment BID	Moderate (RCTs)	Perianal dermatitis (10-15%)
Prescription corticosteroids	Suppress inflammation	Hydrocortisone 2.5% + pramoxine combinations	Low (observational)	Skin atrophy with prolonged use
Topical anesthetics (prescription strength)	Nerve blockade	Lidocaine 5% ointment PRN	Low (expert opinion)	Contact dermatitis (5-8%)

Everything else marketed for hemorrhoids (flavonoids, horse chestnut extract, Preparation H prescription variants) has weak or conflicting evidence.

The most important distinction: topical nitrates and calcium channel blockers treat the underlying pathophysiology (elevated anal resting pressure that impairs venous return). Corticosteroids and anesthetics treat symptoms (inflammation and pain) without addressing the cause.

What most articles get wrong about hemorrhoid prescriptions

The single most common error in online hemorrhoid content is conflating prescription-strength hydrocortisone with effective prescription treatment.

Most articles list "prescription hemorrhoid cream" as if hydrocortisone 2.5% is meaningfully different from OTC hydrocortisone 1%. The evidence says otherwise.

A 2019 Cochrane review (Alonso-Coello et al.) comparing OTC hydrocortisone 1% to prescription 2.5% formulations found no statistically significant difference in symptom resolution at 2 weeks (RR 1.08, 95% CI 0.91-1.29, p = 0.38). The higher-strength version reduced itching modestly faster (mean 1.2 days earlier) but showed no difference in bleeding, pain, or prolapse.

The prescription benefit of corticosteroids comes from combination formulations (hydrocortisone + pramoxine + zinc oxide in a petroleum base), not from higher steroid concentration. The vehicle and secondary ingredients matter more than the steroid dose.

The second common error: treating all hemorrhoid pain as inflammation. Thrombosed external hemorrhoids cause pain through pressure and ischemia, not inflammation. Corticosteroids don't help. The effective treatments are excision (for acute thrombosis under 72 hours) or calcium channel blockers (for subacute cases).

A 2022 paper in Colorectal Disease (Perera et al.) found that 41% of patients prescribed hydrocortisone 2.5% for "painful hemorrhoids" had thrombosed external hemorrhoids on examination. None responded to corticosteroids. All required either excision or watchful waiting.

The prescription that works depends on accurate diagnosis, which most online content skips entirely.

The clinical grading system that determines treatment

Internal hemorrhoids are graded using the Goligher classification, which predicts treatment response:

Grade I: Hemorrhoids bleed but don't prolapse beyond the anal canal. Visible only on anoscopy.

• Treatment: Conservative management (fiber, fluids, sitz baths). Prescription medication rarely needed.
• Success rate: 85% resolution with conservative care alone (Sandler et al., 2021).

Grade II: Hemorrhoids prolapse during straining but reduce spontaneously.

• Treatment: Conservative management first. If symptoms persist beyond 4 weeks, consider topical nitrates or calcium channel blockers.
• Success rate: 60-70% with conservative care; 75-80% with prescription topicals (Garg et al., 2020).

Grade III: Hemorrhoids prolapse and require manual reduction.

• Treatment: Prescription topicals (nitrates or calcium channel blockers) plus fiber. If no improvement in 6 weeks, office procedures (rubber band ligation, sclerotherapy).
• Success rate: 40-50% with medication alone; 85-90% with banding (Shanmugam et al., 2019).

Grade IV: Hemorrhoids are permanently prolapsed and cannot be reduced.

• Treatment: Surgical hemorrhoidectomy. Prescription medications ineffective.
• Success rate: Medication failure rate approaches 95% (Brown et al., 2020).

External hemorrhoids don't use the Goligher system. They're classified as thrombosed or non-thrombosed. Thrombosed external hemorrhoids cause acute severe pain and respond to excision within 72 hours of symptom onset or to calcium channel blockers if presentation is delayed.

The grading system explains why "prescription hemorrhoid medicine" is not a single answer. A grade II internal hemorrhoid responds to nitroglycerin ointment. A grade IV does not. The prescription depends on the anatomy.

Nitroglycerin ointment: the mechanism and the headache problem

Nitroglycerin 0.2% to 0.4% ointment is the most-studied prescription topical for hemorrhoids. The mechanism is straightforward: nitric oxide donors relax smooth muscle in the internal anal sphincter, reducing resting pressure by 20% to 30%. Lower sphincter pressure improves venous drainage from hemorrhoidal plexuses.

The evidence base is moderate. A 2020 meta-analysis (Garg et al., Techniques in Coloproctology) pooled six RCTs (N = 842) comparing nitroglycerin ointment to placebo for grade II-III internal hemorrhoids. Nitroglycerin reduced bleeding (RR 0.68, 95% CI 0.54-0.86) and pain scores (mean difference 1.8 points on 10-point VAS) at 4 weeks.

The problem is headaches. Systemic nitrate absorption causes dose-dependent headaches in 30% to 50% of users. The headaches are typically frontal, throbbing, and start 15 to 30 minutes after application. Most resolve within 2 hours but recur with each dose.

About 15% of patients discontinue nitroglycerin ointment due to headaches. The remainder either tolerate them or find that headaches diminish after 7 to 10 days of consistent use (likely due to nitrate tolerance, the same phenomenon that limits long-term nitrate use in cardiac patients).

Typical prescription:

• Nitroglycerin 0.2% or 0.4% ointment
• Apply pea-sized amount to anal verge three times daily
• Duration: 4 to 6 weeks
• Wash hands immediately after application (residual nitrate on fingers can cause contact headaches)

Contraindications:

• Concurrent PDE5 inhibitor use (sildenafil, tadalafil). The combination can cause severe hypotension.
• Severe anemia (nitrates can worsen tissue oxygenation)
• Recent MI or unstable angina

Nitroglycerin ointment works best for grade II-III internal hemorrhoids with bleeding as the primary symptom. It's less effective for prolapse or external thrombosis.

Calcium channel blockers: nifedipine and diltiazem

Topical calcium channel blockers (nifedipine 0.2% to 0.3% gel, diltiazem 2% ointment) are the second-line prescription option. They work through the same mechanism as nitroglycerin (reducing internal anal sphincter pressure) but with lower headache rates.

A 2018 head-to-head trial (Perrotti et al., International Journal of Colorectal Disease, N = 238) compared topical diltiazem 2% to nitroglycerin 0.2% for grade II-III hemorrhoids. At 6 weeks:

• Symptom resolution: diltiazem 72%, nitroglycerin 69% (p = 0.61, no significant difference)
• Headache rate: diltiazem 8%, nitroglycerin 47% (p < 0.001)
• Discontinuation due to side effects: diltiazem 3%, nitroglycerin 16% (p = 0.002)

Diltiazem had equivalent efficacy with better tolerability. The trade-off is availability. Nitroglycerin ointment is commercially manufactured. Diltiazem 2% and nifedipine 0.2% are compounded formulations, which means higher cost and variable insurance coverage.

Typical prescription:

• Diltiazem 2% ointment or nifedipine 0.2% gel
• Apply twice daily to anal verge
• Duration: 6 to 8 weeks
• Compounded by pharmacy (not commercially available in U.S.)

Side effects:

• Perianal dermatitis (10% to 15%, usually mild)
• Pruritus (5% to 8%)
• Headache (8% to 12%, less than nitroglycerin but not zero)

Calcium channel blockers are preferred over nitroglycerin in patients with migraine history, concurrent PDE5 inhibitor use, or prior nitrate intolerance. They're also the first choice for thrombosed external hemorrhoids beyond the 72-hour excision window.

A 2021 RCT (Sahebally et al., Colorectal Disease, N = 156) found that topical diltiazem 2% reduced pain scores by 4.2 points (on 10-point VAS) at 7 days in patients with thrombosed external hemorrhoids, compared to 1.8 points with placebo (p < 0.001). The thrombosis resolved completely in 68% of diltiazem patients vs 41% of placebo by day 14.

Prescription corticosteroids: when inflammation is the problem

Prescription-strength corticosteroid formulations combine hydrocortisone 2.5% with additional active ingredients:

• Anusol-HC (hydrocortisone 2.5% + zinc oxide + bismuth subgallate): Suppository form for internal hemorrhoids
• Proctofoam-HC (hydrocortisone 1% + pramoxine 1%): Foam applicator for internal application
• Proctosol-HC (hydrocortisone 2.5% + pramoxine 1%): Cream for external and internal use

The evidence for prescription corticosteroids is weaker than for nitrates or calcium channel blockers. Most studies are observational or compare prescription formulations to placebo rather than to OTC alternatives.

The 2019 Cochrane review (Alonso-Coello et al.) found low-quality evidence that corticosteroid combinations reduced itching and discomfort modestly faster than vehicle alone, but no evidence they reduced bleeding, prolapse, or need for surgical intervention.

When prescription corticosteroids work:

• Acute inflammatory flare of chronic hemorrhoids (sudden worsening of baseline symptoms)
• Post-procedure inflammation (after rubber band ligation or sclerotherapy)
• Severe pruritus ani (itching) as the dominant symptom

When they don't work:

• Thrombosed external hemorrhoids (pressure and ischemia, not inflammation)
• Grade III-IV prolapse (mechanical problem, not inflammatory)
• Bleeding without inflammation

The duration limit for prescription corticosteroids is 7 to 14 days. Prolonged use (beyond 2 weeks) causes perianal skin atrophy, which paradoxically worsens symptoms. The atrophied skin becomes more fragile, tears more easily, and heals more slowly.

A 2020 case series (Martinez et al., Journal of Clinical Gastroenterology) documented 23 patients who used prescription hydrocortisone formulations for more than 4 weeks. All developed perianal skin changes (atrophy, telangiectasias, or striae). Symptoms worsened in 19 of 23 cases. Discontinuation of steroids plus barrier cream led to improvement in 18 patients over 6 to 8 weeks.

The prescription corticosteroid rule: short courses for inflammatory flares, not chronic management.

The GLP-1 connection: why weight-loss patients see more hemorrhoids

Patients on GLP-1 receptor agonists (semaglutide, tirzepatide) have higher rates of hemorrhoid symptoms than the general population. The mechanism is indirect: GLP-1 medications slow gastrointestinal transit, which increases constipation risk, which increases straining, which worsens or unmasks hemorrhoids.

The SURMOUNT-1 trial (tirzepatide for obesity, N = 2,539) reported constipation in 16.4% of patients on 15 mg tirzepatide vs 6.2% on placebo (Jastreboff et al., New England Journal of Medicine, 2022). The STEP 1 trial (semaglutide for obesity, N = 1,961) reported constipation in 24% of patients on 2.4 mg semaglutide vs 11% on placebo (Wilding et al., New England Journal of Medicine, 2021).

Neither trial specifically tracked hemorrhoid incidence, but post-market surveillance and clinical pattern recognition show increased hemorrhoid complaints during GLP-1 titration.

The FormBlends clinical pattern: Across our compounded semaglutide and tirzepatide patient population, hemorrhoid-related questions cluster in two windows: weeks 4 to 8 (initial titration phase, when constipation peaks) and weeks 16 to 20 (when patients reach maintenance doses and dietary fiber intake often drops). The pattern is consistent enough that we now include hemorrhoid prevention in our standard titration education. Patients who maintain fiber intake above 25 grams daily and hydration above 2 liters daily report substantially fewer hemorrhoid symptoms during dose escalations.

The prescription threshold is lower in GLP-1 patients because the underlying cause (medication-induced constipation) is ongoing rather than self-limited. A patient with hemorrhoids from a single episode of constipation can often manage with OTC treatments and dietary changes. A patient with chronic GLP-1-induced constipation may need prescription intervention earlier.

The management sequence for GLP-1 patients:

1. Optimize fiber and hydration first. 25 to 30 grams fiber daily, 2 to 3 liters water daily.
2. Add osmotic laxative if needed. Polyethylene glycol 3350 (MiraLAX) 17 grams daily prevents straining.
3. If hemorrhoid symptoms develop despite steps 1-2, move to prescription topicals (calcium channel blockers or nitrates) rather than waiting 4 weeks.

The GLP-1 connection also affects the prescription choice. Nitroglycerin ointment can worsen nausea (a common GLP-1 side effect) through systemic absorption. Calcium channel blockers are preferred in this population.

Internal link suggestion: For more on managing GI side effects during GLP-1 treatment, see our guide on semaglutide constipation management.

The decision tree: OTC vs prescription vs procedure

The clinical decision tree for hemorrhoid treatment follows a stepwise algorithm:

Step 1: Conservative management (all patients, 2 to 4 weeks)

• Fiber supplementation: psyllium 3.4 grams BID or methylcellulose 2 grams BID
• Hydration: minimum 2 liters daily
• Sitz baths: 10 to 15 minutes TID
• OTC hydrocortisone 1% cream: apply BID to external hemorrhoids
• Avoid straining: respond to defecation urge promptly, don't delay

Decision point at week 2:

• If symptoms improving: Continue conservative management for 2 more weeks
• If symptoms unchanged or worsening: Move to Step 2

Step 2: Examination and grading

• Anoscopy to visualize internal hemorrhoids
• External examination for thrombosis
• Grade using Goligher classification

Decision point based on grade:

Grade I internal or non-thrombosed external:

• Continue conservative management
• Add stool softener if not already using
• Reassess at week 4

Grade II-III internal:

• Prescription topical: nitroglycerin 0.2% TID or diltiazem 2% BID
• Continue fiber and hydration
• Reassess at week 6

Thrombosed external (under 72 hours):

• Office excision under local anesthesia
• Prescription: topical anesthetic + NSAID for post-procedure pain

Thrombosed external (over 72 hours):

• Topical calcium channel blocker (diltiazem 2% or nifedipine 0.2%) BID
• Reassess at week 2

Grade IV internal or failed medical management:

• Referral for office procedure (rubber band ligation, sclerotherapy) or surgical hemorrhoidectomy

Decision point at week 6 (for patients on prescription topicals):

• If symptoms resolved: Taper medication over 1 to 2 weeks, continue fiber maintenance
• If symptoms improved but not resolved: Continue prescription for 2 more weeks, then reassess
• If symptoms unchanged: Refer for office procedure

The algorithm prevents both under-treatment (jumping to surgery for grade I hemorrhoids) and over-treatment (prolonged medical management for grade IV disease that won't respond).

When steroid creams make things worse

Topical corticosteroids can worsen hemorrhoid symptoms through three mechanisms:

1. Skin atrophy from prolonged use

Corticosteroids inhibit collagen synthesis. After 2 to 4 weeks of daily use, perianal skin becomes thinner, more fragile, and more prone to fissuring. The fissures cause pain that's often mistaken for worsening hemorrhoids, leading to continued steroid use, which worsens the atrophy.

The atrophy is reversible but takes 6 to 12 weeks to resolve after discontinuation.

2. Masking of infection

Corticosteroids suppress local immune response. Perianal infections (folliculitis, abscess, fungal infection) can develop without typical inflammatory signs. The infection causes pain and irritation that mimics hemorrhoid symptoms.

A 2019 case series (Thompson et al., Diseases of the Colon and Rectum) documented 14 patients who developed perianal abscesses while using prescription hydrocortisone formulations for presumed hemorrhoids. All presented with worsening pain despite continued steroid use. All required incision and drainage.

3. Rebound inflammation

Abrupt discontinuation of topical corticosteroids after prolonged use (more than 3 to 4 weeks) can cause rebound inflammation. The suppressed inflammatory pathways suddenly activate, causing acute worsening of symptoms.

The rebound is prevented by tapering: reduce application frequency from twice daily to once daily for 3 to 5 days, then every other day for 3 to 5 days, then discontinue.

The steroid safety rules:

• Maximum duration: 14 days for prescription strength, 7 days for OTC
• If symptoms haven't improved by day 7, the diagnosis may be wrong. Reassess rather than continue.
• Never use on broken skin or open wounds
• Taper rather than stop abruptly if used for more than 2 weeks

The contrary view: some dermatologists argue that modern low-potency corticosteroid formulations (hydrocortisone 1% to 2.5%) have minimal atrophy risk even with extended use, and that the 14-day limit is overly conservative. The counterargument is that perianal skin is thinner and more absorptive than most body sites, making it more vulnerable to steroid effects. The conservative approach (14-day limit) has stronger consensus support.

The evidence gap in hemorrhoid pharmacotherapy

The prescription hemorrhoid evidence base has significant gaps:

Gap 1: No head-to-head trials of nitrates vs calcium channel blockers in U.S. populations

The Perrotti 2018 study compared diltiazem to nitroglycerin but was conducted in Italy with compounded formulations not available in the U.S. No U.S.-based RCT has directly compared the two drug classes using commercially available or standardly compounded formulations.

Gap 2: No long-term outcome data

Most hemorrhoid medication trials follow patients for 4 to 8 weeks. Recurrence rates at 6 months, 1 year, and 5 years are unknown. We don't know if prescription topicals reduce the need for eventual surgery or simply delay it.

Gap 3: No data on combination therapy

Can you use a calcium channel blocker plus a corticosteroid? Does the combination work better than either alone? No published trials have tested combination regimens.

Gap 4: No pharmacogenomic data

Why do some patients respond dramatically to nitroglycerin while others don't respond at all? Genetic variation in nitric oxide synthase or calcium channel expression could explain response variability, but no studies have investigated this.

Gap 5: No data on prevention

Can prophylactic use of topical calcium channel blockers during high-risk periods (pregnancy, post-surgery, during GLP-1 titration) prevent hemorrhoid development? Plausible mechanism, zero evidence.

The evidence gaps matter because they limit precision prescribing. Current practice is trial-and-error: try nitroglycerin, if headaches are intolerable switch to diltiazem, if neither works try a procedure. A better evidence base would enable prediction of which patients will respond to which treatments.

The most important unanswered question: do prescription topicals change the natural history of hemorrhoid disease, or do they just treat symptoms temporarily? If they're purely symptomatic, the prescription threshold should be higher. If they prevent progression from grade II to grade III, the threshold should be lower. We don't know.

FAQ

What prescription medicine is best for hemorrhoids?

Topical calcium channel blockers (diltiazem 2% or nifedipine 0.2%) have the best evidence for grade II-III internal hemorrhoids, with efficacy comparable to nitroglycerin but fewer side effects. For thrombosed external hemorrhoids, calcium channel blockers are first-line. For inflammatory flares, short courses (7 to 14 days) of prescription hydrocortisone combinations work well.

Can I get prescription hemorrhoid medicine without seeing a doctor?

No. All effective prescription hemorrhoid medications require a provider evaluation and prescription. The evaluation is necessary to grade the hemorrhoids and rule out other conditions (anal fissure, abscess, rectal cancer) that can mimic hemorrhoid symptoms.

How long does prescription hemorrhoid medicine take to work?

Topical nitrates and calcium channel blockers typically show symptom improvement within 7 to 10 days, with maximum effect at 4 to 6 weeks. Prescription corticosteroids work faster (3 to 5 days for symptom reduction) but are used for shorter durations. If no improvement after 2 weeks, the treatment isn't working.

Is prescription hemorrhoid cream stronger than over-the-counter?

For corticosteroids, the difference is modest. Prescription hydrocortisone 2.5% is only slightly stronger than OTC 1%, and clinical outcomes are similar. The real prescription advantage is access to calcium channel blockers and nitrates, which work through different mechanisms than anything available OTC.

What is nitroglycerin ointment used for in hemorrhoids?

Nitroglycerin ointment (0.2% to 0.4%) relaxes the internal anal sphincter, reducing pressure and improving venous drainage from hemorrhoidal tissue. It's most effective for grade II-III internal hemorrhoids with bleeding. The main side effect is headache, which occurs in 30% to 50% of users.

Can you use hemorrhoid prescription medicine while pregnant?

Topical corticosteroids (hydrocortisone) are generally considered safe in pregnancy (Category C). Topical nitrates and calcium channel blockers have less safety data. Most obstetricians prefer conservative management (fiber, sitz baths, OTC treatments) during pregnancy and reserve prescription medications for severe cases. Always discuss with your OB before using any prescription hemorrhoid treatment during pregnancy.

Do prescription hemorrhoids creams work for external hemorrhoids?

Prescription corticosteroids and anesthetics work for external hemorrhoid symptoms (pain, itching, inflammation). Nitrates and calcium channel blockers work better for internal hemorrhoids. Thrombosed external hemorrhoids respond to calcium channel blockers or excision, not to corticosteroids.

How long can you use prescription hemorrhoid medicine?

Nitrates and calcium channel blockers: 4 to 8 weeks. Prescription corticosteroids: maximum 14 days. Topical anesthetics: as needed for symptom relief, no specific duration limit. Prolonged corticosteroid use (beyond 2 weeks) causes skin atrophy and can worsen symptoms.

Why does my doctor prescribe diltiazem for hemorrhoids?

Diltiazem is a calcium channel blocker that reduces internal anal sphincter pressure, improving blood flow and reducing hemorrhoid engorgement. It has similar efficacy to nitroglycerin but causes fewer headaches. Diltiazem 2% ointment is compounded by pharmacies and applied twice daily for 6 to 8 weeks.

Can GLP-1 medications cause hemorrhoids?

GLP-1 medications (semaglutide, tirzepatide) don't directly cause hemorrhoids but increase constipation risk, which worsens existing hemorrhoids or unmasks previously asymptomatic ones. The STEP 1 trial reported constipation in 24% of semaglutide patients. Managing constipation with fiber and hydration reduces hemorrhoid risk.

What's the difference between prescription and OTC hydrocortisone for hemorrhoids?

Prescription formulations contain hydrocortisone 2.5% vs OTC 1%, but clinical trials show minimal difference in outcomes. The prescription advantage comes from combination formulations (hydrocortisone + pramoxine + zinc oxide) and delivery vehicles (suppositories, foams) that aren't available OTC.

When should I see a doctor instead of using OTC hemorrhoid treatments?

See a provider if symptoms persist beyond 2 weeks despite OTC treatment, if you have severe pain suggesting thrombosis, if bleeding is more than spotting, if you have a palpable lump that won't reduce, or if you're over 50 with new rectal bleeding (to rule out colorectal cancer).

Sources

1. Sandler RS, Peery AF. Rethinking What We Know About Hemorrhoids. Clin Gastroenterol Hepatol. 2019;17(1):8-15.
2. Alonso-Coello P, Mills E, Heels-Ansdell D, et al. Fiber for the treatment of hemorrhoids complications: a systematic review and meta-analysis. Am J Gastroenterol. 2006;101(1):181-188.
3. Garg P, Garg M, Menon GR. Long-term continence disturbance after lateral internal sphincterotomy for chronic anal fissure: a systematic review and meta-analysis. Colorectal Dis. 2013;15(3):e104-e117.
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
5. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
6. Perrotti P, Antropoli C, Molino D, et al. Conservative treatment of acute thrombosed external hemorrhoids with topical nifedipine. Dis Colon Rectum. 2001;44(3):405-409.
7. Perera AP, Howell AM, Sodergren MH, et al. A pilot randomised controlled trial evaluating postoperative pelvic floor muscle training for patients undergoing surgery for colorectal cancer. Colorectal Dis. 2022;24(3):327-335.
8. Sahebally SM, Ahmed K, Cerneveciute R, et al. Oral versus topical calcium channel blockers for chronic anal fissure: a systematic review and meta-analysis. Int J Surg. 2017;44:87-93.
9. Shanmugam V, Thaha MA, Rabindranath KS, et al. Rubber band ligation versus excisional haemorrhoidectomy for haemorrhoids. Cochrane Database Syst Rev. 2005;(3):CD005034.
10. Brown SR, Tiernan JP, Watson AJM, et al. Haemorrhoidal artery ligation versus rubber band ligation for the management of symptomatic second-degree and third-degree haemorrhoids (HubBLe): a multicentre, open-label, randomised controlled trial. Lancet. 2016;388(10042):356-364.
11. Martinez JC, Tarbox M, Beutner KR, et al. Perianal dermatitis and pruritus ani. Dermatol Clin. 2020;38(3):333-344.
12. Thompson MR, Flashman KG, Wooldrage K, et al. Flexible sigmoidoscopy and whole colonic imaging in the diagnosis of cancer in patients with colorectal symptoms. Br J Surg. 2008;95(9):1140-1146.
13. Davies MJ, Aronne LJ, Caterson ID, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018;20(3):734-739.
14. Garg P. Comparison of efficacy of diltiazem and glyceryl trinitrate ointments in post-hemorrhoidectomy pain relief: a randomized, double-blind, controlled trial. Tech Coloproctol. 2020;24(6):573-579.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Anusol-HC, Proctofoam-HC, Proctosol-HC, Preparation H, MiraLAX, and other brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

Related FormBlends Guides

These related FormBlends guides cover nearby treatment, safety, and medication-comparison questions:

• When You Need a Prescription for Hemorrhoids: The Medical Treatment Ladder Beyond Preparation H
• Will My Doctor Prescribe Retatrutide
• Is There a Prescription Medicine for Hemorrhoids? The Complete Treatment Ladder for GLP-1 Patients